GlassScriptPhysician profile
Abderrahim Khomani
NPI 1750589529
$6,199.71
in general payments reported to CMS, 2019-2025
53 companies · $66.34 in 2025
The $66.34 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $234 · 2021: $611 · 2022: $1,713 · 2023: $1,361 · 2024: $941 · 2025: $66.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.60 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $558.59 | 2019-2024 | |
| Amgen INC. | $378.10 | 2019-2023 | Kyprolis, Blincyto |
| Celgene Corporation | $346.36 | 2019-2024 | Pomalyst, Reblozyl, Opdualag |
| Janssen Biotech, INC. | $332.29 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| Genentech USA, INC. | $321.00 | 2019-2022 | |
| Pfizer INC. | $319.59 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $314.24 | 2019-2024 | Opdualag |
| Seagen INC. | $309.87 | 2021-2023 | Tukysa, Adcetris |
| Eisai INC. | $302.21 | 2019-2024 | |
| Astellas Pharma US INC | $278.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.40 | 2021-2023 | Iclusig |
| Abbvie INC. | $245.20 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $229.23 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $225.63 | 2019-2024 | Tagrisso, Lynparza |
| Incyte Corporation | $174.70 | 2019-2022 |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abderrahim Khomani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.